… actors purposively engage in the disrupting of institutions. … research and organisational
research, cholesterol lowering drugs, … The food industry invested in research and development to …

… of considering a cholesterol-lowering treatment strategy in … BP (SBP) and a slower rise in
SBP with age than people without … ensure that these short-acting agents would be active during …

… This has prompted the development of new LDL-C lowering drugs in the hope to reduce …
C, lipoprotein (a)), intravascular inflammation or acting by other mechanisms also have a role in …

… It has been known for some time that besides acting on the LDL receptor, SREBPs act to
upregulate protease proprotein convertase subtilisin/kexin type 9 (PCSK9). The protease …

… , placebo-controlled study that enrolled 269 patients with a history of statin intolerance and
… Treatment with bempedoic acid was well tolerated as rates of treatment-emergent adverse …

… The second section examines the recent history of the … every 1 percent reduction in cholesterol
lowering the coronary risk by … Other actors include scientists who dispute this claim to fact, …

… and our arrangements with organizations such as the Copyright … metabolism on the fetal
development 430 Summary 436 … and pathogens 687 Cholesterol-lowering agents as potential …

… availability of affordable cholesterol-lowering therapies which … , its consequences and the
development of new preventive therapies [1,… The main actors of the health system committed to …

… that berberine lowers blood lipids levels by acting on the 3′-… been identified as a novel
cholesterol-lowering drug. It could … preparation development project of the scientific research …

… The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo
identified an active compound (compactin) that inhibited cholesterol biosynthesis from the culture …